HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours

Phase IIa study of HX009+ IN10018 in combination with or without standard chemotherapy in patients with advanced solid tumours including biliary tract malignancies and malignant melanoma

Trial Details

NCT ID
NCT06708663
Phase
PHASE1 / PHASE2
Sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • HX009+IN10018
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Voluntarily participate in the trial and sign the informed consent form;
  • male or female, age at 18 to 70 years (including borderline value) ;
  • expected survival ≥ 12 weeks;
  • ECOG score 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →